Showing papers in "Hepatology in 2021"

TL;DR: Primary prevention efforts aimed at decreasing the prevalence of obesity and diabetes and controlling mycotoxin growth, are just as urgently required for HCC.

TL;DR: An evidence-based justification for bleeding risk assessment in patients with cirrhosis prior to invasive procedures, including current concepts in preprocedural testing and laboratory analysis and their role in predicting bleeding complications are explained.

TL;DR: The creation of a true international consensus group to include all the relevant scientific liver societies, patient advocacy organizations, bio‐pharmaceutical industry, regulatory agencies and policy makers is recommended to move the field forward.

TL;DR: A framework to facilitate capturing the efficacy of novel therapeutic strategies with the goal of improving the outcomes of patients suffering from Hepatocellular carcinoma is articulate.

TL;DR: The currently available technologies for CTC detection and isolation, their utility in the clinical management of HCC patients, their limitations, and future directions of research are discussed.

TL;DR: The first American Association for the Study of Liver Diseases (AASLD) Practice Guidance on the management of malnutrition, frailty, and sarcopenia in patients with cirrhosis is presented in this paper.

TL;DR: It is proposed that hepatic lipotoxicity and multiple events beyond the liver, such as adipose tissue inflammation and gastrointestinal hits including dysbiosis, fuel the evolution of non-alcoholic fatty liver disease (NAFLD).

TL;DR: Evaluated the trend, etiology, and outcomes associated with liver biochemistries in COVID‐19, which leads to elevated LiverCoronavirus disease 2019 in approximately half of patients on presentation.

TL;DR: The LEGACY study as mentioned in this paper evaluated objective response rate (ORR) and duration of response (DoR) in patients with solitary unresectable HCC treated with yttrium-90 glass microspheres.

TL;DR: This work aimed to characterize surveillance use among patients with cirrhosis and the efficacy of interventions to increase surveillance.

TL;DR: Advanced fibrosis attributable to NASH is a leading cause of end‐stage liver disease and the use of statins to treat this disease is recommended.

TL;DR: Saroglitazar as discussed by the authors improved insulin sensitivity and lipid and glycemic parameters in patients with NAFLD/NASH by using a dual peroxisome proliferator activated receptor-α/γ agonist.

TL;DR: A detailed review of the currently available COVID-19 vaccines and those in development, including mRNA, adenoviral vectors, and recombinant protein approaches, can be found in this article.

TL;DR: It is shown that fructose intake causes protein nitration of intestinal TJ and AJ proteins, resulting in increased gut leakiness, endotoxemia, and steatohepatitis with liver fibrosis, at least partly, through a CYP2E1‐dependent manner.

TL;DR: The development and progression of hepatocellular carcinoma (HCC) is dependent on its local microenvironment and Tumor‐associated macrophages (TAMs) are deemed a key factor for the tumor micro environment and attribute to contribute to tumor aggressiveness.

TL;DR: The features of this zoonosis in Hong Kong are described and the first case of human HEV‐C1 infection was recently discovered in Hong Hong Kong.

TL;DR: Zhang et al. as mentioned in this paper investigated the effect of the combination of lenvatinib and pembrolizumab in hepatocellular carcinoma (HCC) and found that high levels of FGFR4 and Tregs infiltration sensitized tumor to the combination treatment.

TL;DR: Fecal microbiota transplant (FMT) could be a promising approach for alcohol use disorder associated with microbial alterations that worsen with cirrhosis.

TL;DR: Nonalcoholic fatty liver disease is characterized by accumulation of excessive triglycerides (TGs) in hepatocytes, and N6‐methyladenosine (m6A) RNA methylation is the most common internal modification in eukaryotic mRNA.

TL;DR: In this paper, the authors investigated the cellular crosstalk among CAFs, tumor cells, and tumor-associated neutrophils (TANs) during different stages of HCC pathogenesis.

TL;DR: The status on biomarker development for HCC and CCA is summarized, with several therapeutic targets have been identified in CCA, and biomarker‐driven therapies are currently under evaluation in phase 2/3 clinical trials.

TL;DR: Poly rC binding protein 1 (PCBP1) is a multifunctional protein that serves as a cytosolic iron chaperone, binding and transferring iron to recipient proteins in mammalian cells.

TL;DR: Current understandings of the tumor microenvironment and intercellular communications in CCA and their role in tumor progression are summarized.

TL;DR: There is a critical need for improved tools to assess liver pathology in order to risk stratify NASH patients and monitor treatment response.

TL;DR: In vivo studies showed that increased circ-CCAC1 levels in circulating EVs and cells accelerated both CCA tumorigenesis and metastasis and may be an important biomarker/therapeutic target for CCA.

TL;DR: The management and prognosis of hepatobiliary malignancies vary widely based on the stage of presentation, with surgical options providing the possibility of definitive cure in patients presenting with early‐stage disease.

TL;DR: The aim of this study was to examine how myeloid‐specific IL‐6 signaling affects NAFLD by the regulation of antifibrotic microRNA‐223 (miR‐223) in myeloids cells.

TL;DR: It is shown that hepatitis B virus transcripts are modified by N6 methyladenosine (m6A) addition, which affects m6A modification of several host RNAs, including phosphatase and tensin homolog (PTEN), a well‐known tumor suppressor.

TL;DR: A focused review of liver biopsy evaluation in fatty liver disease in subjects with presumed NAFLD for practicing clinical hepatologists and pathologists to provide succinct and specific means for reporting the histopathologic elements of NASH.